JP7073109B2 - ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法 - Google Patents

ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法 Download PDF

Info

Publication number
JP7073109B2
JP7073109B2 JP2017568143A JP2017568143A JP7073109B2 JP 7073109 B2 JP7073109 B2 JP 7073109B2 JP 2017568143 A JP2017568143 A JP 2017568143A JP 2017568143 A JP2017568143 A JP 2017568143A JP 7073109 B2 JP7073109 B2 JP 7073109B2
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
cells
compound
cpg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017568143A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018519831A5 (cg-RX-API-DMAC7.html
JP2018519831A (ja
Inventor
コルティレフスキ，マルチン・トマシュ
シフィデルスキ，ピオトル・マレク
モレイラ，デイソン・フリアカ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of JP2018519831A publication Critical patent/JP2018519831A/ja
Publication of JP2018519831A5 publication Critical patent/JP2018519831A5/ja
Priority to JP2022077341A priority Critical patent/JP7459168B2/ja
Application granted granted Critical
Publication of JP7073109B2 publication Critical patent/JP7073109B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017568143A 2015-07-02 2016-06-30 ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法 Active JP7073109B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022077341A JP7459168B2 (ja) 2015-07-02 2022-05-10 ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562187878P 2015-07-02 2015-07-02
US62/187,878 2015-07-02
US201562264026P 2015-12-07 2015-12-07
US62/264,026 2015-12-07
PCT/US2016/040361 WO2017004357A1 (en) 2015-07-02 2016-06-30 Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022077341A Division JP7459168B2 (ja) 2015-07-02 2022-05-10 ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法

Publications (3)

Publication Number Publication Date
JP2018519831A JP2018519831A (ja) 2018-07-26
JP2018519831A5 JP2018519831A5 (cg-RX-API-DMAC7.html) 2019-08-08
JP7073109B2 true JP7073109B2 (ja) 2022-05-23

Family

ID=57609287

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017568143A Active JP7073109B2 (ja) 2015-07-02 2016-06-30 ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法
JP2022077341A Active JP7459168B2 (ja) 2015-07-02 2022-05-10 ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022077341A Active JP7459168B2 (ja) 2015-07-02 2022-05-10 ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法

Country Status (6)

Country Link
US (3) US10758624B2 (cg-RX-API-DMAC7.html)
EP (1) EP3316894A4 (cg-RX-API-DMAC7.html)
JP (2) JP7073109B2 (cg-RX-API-DMAC7.html)
CN (2) CN107980001B (cg-RX-API-DMAC7.html)
CA (1) CA2991052A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017004357A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016115500A1 (en) * 2015-01-16 2016-07-21 City Of Hope Cell penetrating antibodies
CN114525279A (zh) 2015-04-22 2022-05-24 米纳治疗有限公司 C/EBP α SARNA组合物和使用方法
JP7073109B2 (ja) * 2015-07-02 2022-05-23 シティ・オブ・ホープ ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法
WO2018145086A1 (en) 2017-02-06 2018-08-09 Mpeg La, Llc Multimeric oligonucleotides having decreased kidney clearance
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
US11554178B2 (en) 2017-06-30 2023-01-17 City Of Hope Compositions and methods of modulating macrophage activity
EP3679139B1 (en) 2017-09-08 2022-11-02 MiNA Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
CN113584027B (zh) * 2018-04-10 2025-01-10 中美瑞康核酸技术(南通)研究院有限公司 一种激活p21基因表达的方法
WO2019241766A1 (en) * 2018-06-15 2019-12-19 City Of Hope Oligonucleotide-based proteolysis targeting chimera
CN109762042B (zh) * 2018-09-21 2022-04-08 河北艾克美冀生物科技有限公司 一种治疗癌症的药物、其合成方法和应用
CA3132505A1 (en) * 2019-03-04 2020-09-10 Mpeg La, L.L.C. Multimeric oligonucleotides with enhanced bioactivity
EP4003423A4 (en) * 2019-07-26 2024-03-06 MiNA Therapeutics Limited Compositions and methods of using c/ebp alpha sarna
KR102433981B1 (ko) * 2020-12-15 2022-08-19 대구가톨릭대학교산학협력단 HIF-1α 및 STAT5 전사인자를 억제하는 합성 디코이 올리고핵산 및 이를 유효성분으로 함유하는 아토피 피부염의 예방 또는 치료용 약학적 조성물
CN117377764A (zh) * 2021-02-08 2024-01-09 中美瑞康核酸技术(南通)研究院有限公司 多价寡核苷酸试剂及其使用方法
WO2023034853A2 (en) * 2021-08-31 2023-03-09 City Of Hope Oligonucleotides having 6-thio-2'-deoxyguanosine residues and uses thereof
CN114908094B (zh) * 2022-05-31 2024-03-12 中山大学 一类反义寡核苷酸分子及其在制备治疗恶性肿瘤药物中的应用
EP4599065A2 (en) * 2022-10-07 2025-08-13 City of Hope Double-stranded oligonucleotides and methods of use
EP4627086A2 (en) * 2022-11-29 2025-10-08 Lonza Sales AG Methods of using extracellular vesicle-aso targeting stat6
CN118480552B (zh) * 2024-01-18 2024-10-01 成都先衍生物技术有限公司 一种靶向CEBPA基因表达的saRNA及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160298113A1 (en) 2013-11-22 2016-10-13 Mina Therapeutics Limited C/ebp alpha short activating rna compositions and methods of use

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DE69212850T2 (de) 1991-01-15 1997-03-06 Alcon Lab Inc Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6423493B1 (en) * 1998-10-26 2002-07-23 Board Of Regents The University Of Texas System Combinatorial selection of oligonucleotide aptamers
US6159694A (en) 1999-04-08 2000-12-12 Isis Pharmaceuticals Inc. Antisense modulation of stat3 expression
ITRM20030149A1 (it) * 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US20070265220A1 (en) * 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
AU2005248410B2 (en) * 2004-05-27 2010-04-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Differential expression of molecules associated with acute stroke
CA2604532C (en) * 2005-04-15 2017-03-07 The Regents Of The University Of California Small activating rna molecules and methods of use
US8748405B2 (en) * 2007-01-26 2014-06-10 City Of Hope Methods and compositions for the treatment of cancer or other diseases
WO2008094254A2 (en) 2007-01-26 2008-08-07 City Of Hope Methods and compositions for the treatment of cancer or other diseases
WO2009018332A1 (en) * 2007-08-01 2009-02-05 Alnylam Pharmaceuticals, Inc. Single-stranded and double-stranded oligonucleotides comprising a metal-chelating ligand
CA2745811C (en) * 2008-12-04 2021-07-13 Joseph Collard Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
WO2012128785A1 (en) 2011-03-22 2012-09-27 City Of Hope Methods and compositions for the treatment of cancer or other diseases
PE20142463A1 (es) * 2011-04-01 2015-01-22 Isis Pharmaceuticals Inc Modulacion de la expresion del transductor de senales y activador de la transcripcion 3 (stat3)
WO2014047649A1 (en) * 2012-09-24 2014-03-27 The Regents Of The University Of California Methods for arranging and packing nucleic acids for unusual resistance to nucleases and targeted delivery for gene therapy
RS58576B1 (sr) * 2012-10-31 2019-05-31 Ionis Pharmaceuticals Inc Tretman raka
AU2014236370C1 (en) * 2013-03-14 2019-01-17 City Of Hope 5-bromo-indirubins
WO2015077657A2 (en) 2013-11-22 2015-05-28 City Of Hope Stat3 inhibitors and uses thereof
JP7073109B2 (ja) * 2015-07-02 2022-05-23 シティ・オブ・ホープ ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160298113A1 (en) 2013-11-22 2016-10-13 Mina Therapeutics Limited C/ebp alpha short activating rna compositions and methods of use

Also Published As

Publication number Publication date
EP3316894A1 (en) 2018-05-09
US20220401563A1 (en) 2022-12-22
CN107980001B (zh) 2021-12-17
EP3316894A4 (en) 2019-06-19
JP2022116006A (ja) 2022-08-09
JP7459168B2 (ja) 2024-04-01
CN114224907A (zh) 2022-03-25
US10758624B2 (en) 2020-09-01
CN107980001A (zh) 2018-05-01
CA2991052A1 (en) 2017-01-05
US11464865B2 (en) 2022-10-11
US20210038733A1 (en) 2021-02-11
WO2017004357A1 (en) 2017-01-05
JP2018519831A (ja) 2018-07-26
US20180185497A1 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
JP7459168B2 (ja) ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法
JP7038045B2 (ja) ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにその使用方法
WO2018192505A1 (en) Immunomodulatory polynucleotides and uses thereof
JP2024505035A (ja) 中枢神経系における遺伝子発現を阻害するための組成物および方法
JP2024502432A (ja) がん治療のための鋳型指向性免疫調節
JP2024508119A (ja) Ｒｎａｉコンジュゲートおよびその使用
JP7295838B2 (ja) ホスホロチオエートコンジュゲートペプチド及びその使用方法
JP2025509502A (ja) Ｓｔａｔ３標的化オリゴヌクレオチドおよびｐｄ－ｌ１阻害剤の組み合わせ
JP2019163302A (ja) 免疫賦活活性を有する核酸多糖複合体の抗腫瘍薬としての応用
JP2024539435A (ja) がんの免疫療法的治療のためのｃＧＡＳ－ＳＴＩＮＧ及びＳＴＡＴ３経路変調のための球状核酸
US20230203504A1 (en) Immunomodulatory polynucleotides and uses thereof
TW202511486A (zh) 用於程式化死亡配體受體（ｐｄ－ｌ１）表現之組成物和方法
JP2025538419A (ja) Ｓｔａｔ３標的化オリゴヌクレオチドおよびその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190626

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200714

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210706

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211005

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220511

R150 Certificate of patent or registration of utility model

Ref document number: 7073109

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250